The main purpose of this study is to find out whether changing the hospital policy to allow switch from glycopeptide antibiotics (given by intravenous drip), to an equally effective oral antibiotic (linezolid) will enable patients who are otherwise well enough to be discharged from hospital sooner. The secondary objectives are 1. To identify those patients who could potentially be discharged on an oral agent from those being treated with a glycopeptide, thus helping target this approach most effectively 2. To evaluate the cost involved and compare this with the costs that would have taken place if use of an oral agent and discharge had not occurred.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To identify the percentage of patients currently prescribed IV glycopeptides who could be discharged earlier if an oral agent was used
Timeframe: Period between IV oral switch and discharge, at least 24 hours